Ascendis Pharma A/S (ASND) Stock Forecast & Price Target

$126.03 -1.64 (-1.28%)

(As of 11/13/2024 ET)

Ascendis Pharma A/S - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 13 Analyst Ratings

Sell
0

Hold
1

Buy
12

Based on 13 Wall Street analysts who have issued ratings for Ascendis Pharma A/S in the last 12 months, the stock has a consensus rating of "Buy." Out of the 13 analysts, 1 has given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for ASND.

Consensus Price Target

$195.92
55.46% Upside

According to the 13 analysts' twelve-month price targets for Ascendis Pharma A/S, the average price target is $195.92. The highest price target for ASND is $289.00, while the lowest price target for ASND is $140.00. The average price target represents a forecasted upside of 55.46% from the current price of $126.03.

ASND Analyst Ratings Over Time

Type	Current Forecast 11/15/23 to 11/14/24	1 Month Ago 10/16/23 to 10/15/24	3 Months Ago 8/17/23 to 8/16/24	1 Year Ago 11/15/22 to 11/15/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	12 Buy rating(s)	10 Buy rating(s)	6 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$195.92	$195.00	$184.64	$140.43
Forecasted Upside	55.46% Upside	53.18% Upside	32.98% Upside	51.05% Upside
Consensus Rating	Buy	Moderate Buy	Moderate Buy	Moderate Buy

2024 Election Year Stocks: Uncover Hidden Gems! (Ad)

In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.

Secure your copy now by clicking this link.

ASND Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ASND Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Ascendis Pharma A/S Stock vs. The Competition

Type	Ascendis Pharma A/S	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	54.57% Upside	26,070.75% Upside	7.80% Upside
News Sentiment Rating	Positive News See Recent ASND News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/4/2024	Wedbush 4 of 5 stars	Y. Zhong Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
11/4/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$170.00 ➝ $170.00	+35.70%
10/23/2024	JPMorgan Chase & Co. 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$180.00 ➝ $174.00	+34.81%
10/21/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Werber Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$157.00 ➝ $160.00	+26.55%
9/23/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$175.00 ➝ $191.00	+28.90%
9/17/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$178.00 ➝ $207.00	+42.41%
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad) As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention. 👉 Click here to access your FREE report now!
9/17/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$264.00 ➝ $289.00	+98.82%
9/17/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$180.00 ➝ $200.00	+39.63%
9/17/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$180.00 ➝ $190.00	+32.64%
9/17/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Clark-Gartner Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$191.00 ➝ $205.00	+43.12%
8/13/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$174.00 ➝ $196.00	+41.50%
5/31/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$200.00	+45.51%
5/16/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$116.00 ➝ $140.00	+13.97%
10/9/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
4/28/2023	3M Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
4/3/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral
11/14/2022	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$168.00 ➝ $148.00	+33.57%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:55 AM ET.

ASND Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Ascendis Pharma A/S is $195.92, with a high forecast of $289.00 and a low forecast of $140.00.
: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There is currently 1 hold rating, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ASND shares.
: According to analysts, Ascendis Pharma A/S's stock has a predicted upside of 55.46% based on their 12-month stock forecasts.
: Over the previous 90 days, Ascendis Pharma A/S's stock had 3 upgrades by analysts.
: Ascendis Pharma A/S has been rated by research analysts at Bank of America, Cantor Fitzgerald, Citigroup, Evercore ISI, JPMorgan Chase & Co., Oppenheimer, TD Cowen, The Goldman Sachs Group, Wedbush, and Wells Fargo & Company in the past 90 days.
: Analysts like Ascendis Pharma A/S more than other "medical" companies. The consensus rating for Ascendis Pharma A/S is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ASND compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Central Bank Abandons USD (Ad)

Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.

Click here now to get your free 'Protect Your Wealth' Guide.

This page (NASDAQ:ASND) was last updated on 11/14/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ascendis Pharma A/S (ASND) Stock Forecast & Price Target